Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
300.2
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.5
Face value
--
Shares outstanding
64,532,100
CFO
$-345.41 Mln
EBITDA
$-402.04 Mln
Net Profit
$-435.02 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GlycoMimetics (GLYC)
| -46.7 | -46.3 | -49.7 | -49.5 | -37.4 | -46.8 | -33.3 |
|
BSE Sensex*
| 4.1 | -1.1 | 9.8 | 5.8 | 16.6 | 19.4 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
GlycoMimetics (GLYC)
| -89.3 | -22.1 | 110.4 | -61.7 | -28.9 | -44.1 | -43.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GlycoMimetics (GLYC)
|
13.3 | 10.1 | 0.1 | -29.5 | -39,489.2 | -1.7 | -- | 300.2 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.7 | 3.9 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.7 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.6 | |
| 25.4 | 10,314.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.3 | 1.9 |
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland. Address: P.O. Box 65, Monrovia, MD, United... States, 21770 Read more
CEO, President & Director
Mr. Harout Semerjian
CEO, President & Director
Mr. Harout Semerjian
Headquarters
Monrovia, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GlycoMimetics Inc (GLYC) stood at $ 11,981 Mln as on 31-Mar-25
The share price of GlycoMimetics Inc (GLYC) is $13.27 (NASDAQ) as of 17-Jun-2025 09:30 EDT. GlycoMimetics Inc (GLYC) has given a return of -37.36% in the last 3 years.
GlycoMimetics Inc (GLYC) has a market capitalisation of $ 10 Mln as on 16-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of GlycoMimetics Inc (GLYC) is 300.17 times as on 16-Jun-2025, a 10815% premium to its peers’ median range of 2.75 times.
Since, TTM earnings of GlycoMimetics Inc (GLYC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GlycoMimetics Inc (GLYC) and enter the required number of quantities and click on buy to purchase the shares of GlycoMimetics Inc (GLYC).
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland. Address: P.O. Box 65, Monrovia, MD, United States, 21770
The CEO & director of Mr. Harout Semerjian. is GlycoMimetics Inc (GLYC), and CFO & Sr. VP is Mr. Harout Semerjian.
There is no promoter pledging in GlycoMimetics Inc (GLYC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| GlycoMimetics Inc. (GLYC) | Ratios |
|---|---|
|
Return on equity(%)
|
-1.74
|
|
Operating margin(%)
|
-39489.19
|
|
Net Margin(%)
|
-54517.3
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GlycoMimetics Inc (GLYC) was $0 Mln.
$-2.43
(
